Salvador Hernandez
Family Medicine · Indio, CANPI 1477819829
Payments from drug & device makers
Across 76 payments — averaging $51.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$800
- GSK$380
- Bayer$378
- Novo Nordisk$305
- Medtronic$284
- AstraZeneca$268
- plus $1K from 16 others
What the payments were for
- Travel & lodging$2847%
- Food & beverage$3,57792%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $800 |
| GSK | 5 | $380 |
| Bayer | 7 | $378 |
| Novo Nordisk | 10 | $305 |
| Medtronic | 1 | $284 |
| AstraZeneca | 3 | $268 |
| Amarin Pharma, Inc. | 12 | $265 |
| Johnson & Johnson | 2 | $229 |
| Si-bone, Inc. | 1 | $134 |
| Merck | 1 | $130 |
| Astellas Pharma US Inc | 1 | $124 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Sunovion Pharmaceuticals Inc. | 1 | $121 |
| Boehringer Ingelheim | 1 | $119 |
| Lilly USA, LLC | 2 | $91 |
| Heartflow, Inc. | 1 | $41 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $13 |
| AbbVie | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$337
- ADVISA DR MRI SURESCAN$284
- XARELTO$229
- Repatha$223
- iFuse Implant$134
- PNEUMOVAX 23$130
- BREZTRI$126
- FARXIGA$125
- TRELEGY ELLIPTA$125
- MYRBETRIQ$124
- INJECTAFER$124
- Vascepa$123
- SHINGRIX$122
- RYBELSUS$122
- APTIOM$121
- JARDIANCE$119
- EVENITY$119
- Prolia$119
- Tresiba$117
- Otezla$102
How this compares
$3,885 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 177 | $200,697 |
| JardianceEmpagliflozin | 141 | $171,053 |
| FarxigaDapagliflozin Propanediol | 106 | $108,981 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $73,652 |
| MyrbetriqMirabegron | 82 | $70,016 |
| EliquisApixaban | 53 | $66,507 |
| TrulicityDulaglutide | 43 | $66,252 |
| RybelsusSemaglutide | 29 | $65,597 |
| OzempicSemaglutide | 38 | $51,998 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $32,525 |
| GemtesaVibegron | 22 | $24,149 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $23,170 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $22,439 |
| TradjentaLinagliptin | 22 | $19,051 |
| KerendiaFinerenone | 11 | $17,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $130 | $200,697177 claims |
| Boehringer IngelheimJardiance, Tradjenta | $119 | $190,104163 claims |
| Novo NordiskRybelsus, Ozempic | $305 | $117,59567 claims |
| AstraZenecaFarxiga | $268 | $108,981106 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $91 | $77,74455 claims |
| Astellas Pharma US IncMyrbetriq | $124 | $70,01682 claims |
| PfizerEliquis | $13 | $66,50753 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $380 | $50,04969 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $6 | $24,14922 claims |
| BayerKerendia | $378 | $17,36811 claims |
| Johnson & JohnsonXarelto | $229 | $16,27821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Indio
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.